表3全球第三代BCR-ABL抑制剂的竞争格局,数据源于亚盛医药-港股公司首次覆盖报告:厚积薄发逐步迈向全球化Biopharma-241010(37页).pdf。
FULVESTRANT (ER antagonist) GNF-7 (BCR-ABL inhibitor) CB BELINOSTAT (HDAC inhibitor) NA BML-210 (HDAC inhibitor) LAQ824 (HDAC inhibitor) GNF-5 (BCR-ABL inhibitor) YM155 (Sepantronium Bromide) (Survivin抑制剂) CASPASE-9 antibody (mouse monoclonal antibody) CASPASE-3 antibody (rabbit polyclonal...
Because the commercial BML-275 (5 mg/300 USD) is too expensive, a synthetic route for the preparation of BML-275 was designed as shown in Scheme 1. The condensation of 2-bromomalonaldehyde 1 with 3-aminopyrazole 2 to afford intermediate pyrazolo[1,5-a]pyrimidine 3,33 which underwent Pd...
Okabe M, Oita M, Kunieda Y, Matuura J, Sakurada K, Mat- sushima S, Kakinuma M, Miyazaki T (1989) Bcr rearrange- ment and c-abl gene expression on Phi-positive hybrid acute leukemia with simultaneous proliferation of lymphoid and myeloid blasts. Blur 58:241-246...